ESCAPE Bio

Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases.

Escape Bio's pipeline includes candidates targeting known genetic drivers of multiple diseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4.

E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States.

ESCAPE Bio headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical sector. The company focuses on Biotechnology and has secured $9.0B in funding across 48 round(s). With a team of 11-50 employees, ESCAPE Bio is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - ESCAPE Bio, raised $63.0M. Discover more about their projects, partnerships, and impact on our platform.